Premier Lab Solutions

Premier Lab Solutions was paid $8.87M by Medicaid between Jan 2018 and Nov 2023, across 80 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 55% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Arizona

Rank by total paid#7 of 67

Median peer was paid$89K

This provider vs. median99×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	2,401	$33K
2019	900	$3K
2020	37,792	$926K
2021	180,037	$2.92M
2022	83,127	$4.63M
2023	14,750	$359K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	55%	64,194	22,751	$4.86M
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	12%	17,103	10,431	$1.05M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	6.7%	43,353	13,475	$591K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	4.3%	9,495	3,304	$381K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	3.9%	8,555	3,540	$347K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	2.9%	16,510	10,430	$259K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	2.7%	9,207	3,470	$239K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	1.1%	9,425	4,264	$94K
87426	Infectious agent antigen detection, SARS-CoV-2 (COVID-19)	<1%	1,972	1,730	$60K
80338		<1%	4,238	1,500	$38K
80322		<1%	3,732	1,000	$37K
80355		<1%	4,294	1,550	$37K

68 more codes

80366		<1%	4,291	$37K
80334		<1%	3,470	$35K
80337		<1%	3,532	$35K
80323		<1%	3,477	$34K
80361		<1%	4,423	$34K
80356		<1%	4,420	$33K
80365		<1%	4,227	$33K
80346		<1%	3,865	$33K
80360		<1%	3,791	$33K
80348		<1%	3,794	$33K
80359		<1%	3,795	$33K
80358		<1%	3,769	$33K
80345		<1%	3,769	$33K
80324		<1%	3,878	$33K
80368		<1%	6,443	$33K
80363		<1%	3,741	$33K
80372		<1%	3,769	$33K
80353		<1%	3,808	$33K
80373		<1%	3,779	$33K
80370		<1%	3,613	$33K
80371		<1%	3,478	$32K
80349		<1%	3,547	$32K
80357		<1%	3,472	$32K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	<1%	1,282	$27K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	182	$13K
80074		<1%	1,438	$12K
80050	General health panel	<1%	1,235	$9K
80343		<1%	524	$7K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	300	$5K
86480		<1%	219	$4K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	235	$4K
86703		<1%	1,394	$4K
86769		<1%	96	$3K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	1,262	$3K
80053	Comprehensive metabolic panel	<1%	843	$3K
87581		<1%	235	$2K
87486		<1%	235	$2K
84443	Thyroid stimulating hormone (TSH)	<1%	489	$2K
80332		<1%	3,634	$2K
G2024	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source	<1%	422	$1K
80336		<1%	3,477	$901.15
80321		<1%	3,836	$881.04
80333		<1%	3,478	$866.99
80335		<1%	3,469	$796.99
80364		<1%	767	$790.00
80362		<1%	3,472	$774.19
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	82	$690.60
80369		<1%	611	$680.00
83690		<1%	422	$678.55
80156		<1%	217	$627.84
82150		<1%	578	$593.28
80048	Basic metabolic panel (calcium, ionized)	<1%	299	$584.85
84481		<1%	87	$408.27
36415	Collection of venous blood by venipuncture	<1%	234	$378.03
82607		<1%	83	$361.66
P9604	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge	<1%	510	$339.87
84439		<1%	86	$224.32
85027		<1%	120	$208.35
80159		<1%	14	$179.08
80347		<1%	65	$136.80
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	50	$133.75
82248		<1%	87	$126.47
86317		<1%	253	$96.92
86592		<1%	81	$96.28
82247		<1%	42	$3.90
G0471	Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha)	0%	252	$0.00
80354		0%	66	$0.00
83992		0%	15	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialOLTROGGE, JONI (OWNER)